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Toxic epidermal necrolysis (TEN) is an uncommon and severe cutaneous adverse drug reaction that
causes disseminated necrosis of epidermal cells and mucocutaneous detachment. Here, we report the
case of a 32-year-old man with human immunodeﬁciency virus infection who presented with gener-
alized violaceous macules and blister formation 4 days after the administration of mefenamic acid and
amoxicillin for a dental procedure. Additional symptoms included oral ulcers and conjunctivitis. Results
of skin biopsy were compatible with StevenseJohnson syndrome (SJS). SJS progressed to TEN within 2
days. Etanercept treatment showed a dramatic improvement in the symptoms of mucocutaneous lesions.
To our knowledge, this is the ﬁrst report on the treatment of TEN using etanercept in a human immu-
nodeﬁciency virus-positive patient.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
StevenseJohnson syndrome (SJS) and toxic epidermal necrolysis
(TEN) are severe cutaneous adverse drug reactions that cause
disseminated epidermal necrosis. Both the conditions are associ-
ated with rapid generalized mucocutaneous detachment and can
potentially result in death.1
Individuals infected with human immunodeﬁciency virus (HIV)
are particularly susceptible to the development of severe adverse
cutaneous drug reactions such as TEN and SJS.2,3 Patientswith SJS or
TEN often receive systemic steroids for treating skin inﬂammation.
However, complications because of steroid use such as infections
and poor wound healing are a concern. Here, we report the case of
an HIV-positive patient diagnosed with TEN based on the results of
skin biopsy. When the patient was treated with etanercept,
complete resolution of symptoms with no complications was seen.
Case report
A 32-year-old, HIV-seropositive but asymptomatic man presented
to our emergency department with generalized skin eruptions and
fever that had persisted for 1 day. He had been diagnosed with HIVer 199, Dunhua North Road,
þ886 2 27135211 3397; fax:
Chung).
iwanese Dermatological Associatioinfection in 2004 and had started receiving highly active anti-
retroviral medications in 2006. He had stopped taking his medi-
cation and missed his HIV follow-up appointment 7 months before
he presented to our emergency department. He had no occurrence
of opportunistic infections during the previous 7 months.
The patient had undergone a dental procedure 4 days before
presenting to our facility. Mefenamic acid and amoxicillin were
prescribed for prophylactic use on the same day. He was not taking
any Chinese herbs, health products, or other drugs. A high fever
(>40C) was noted 1 day before presentation. The sudden onset of
generalized, painful, erythematous skin eruptions with blisters
developed over the following 6 hours.
Physical examination revealed dissemination of generalized
erythematous macules with a central purpuric hue (termed
“atypical target lesions”) on the patient’s trunk, on all four limbs,
and face (Figure 1). Some macules were conﬂuent, forming patches
with bullae. Epidermal detachment involved 9% of the total body
surface area (TBSA). There were multiple ulcers on the lips and oral
mucosa. Bilateral conjunctivitis was also noted. Lymphadenopathy
was not observed. Results of laboratory examinations showed
a normal white blood cell count (7800 cells/mL; normal range,
3900e10,600 cells/mL), elevated serum creatinine level (1.36 mg/
dL; normal range, 0.64e1.27 mg/dL), elevated alanine transaminase
level (42 U/L; normal range, 0e36 U/L), normal blood urine
nitrogen (13.6 mg/dL; normal range, 6e21 mg/dL), elevated C-
reactive protein level (10.26 mg/L; normal range, <5 mg/L), normal
fasting blood glucose level (90 mg/dL; normal range, 70e120 mg/n. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Disseminated atypical target lesions with conﬂuent patches were noted on
the patient’s trunk and on all four limbs. There were also numerous bullae on the
abdomen.
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elevated concentration of HIV RNA (20,789 copies/mL; normal
range, negative). Results of arterial blood gas examination showed
a normal bicarbonate level (25.9 mm/L; normal range, 22e26 mm/
L), while urine analysis revealed the presence of 1þ protein and
trace glucose but not pyuria. A chest X-ray was normal, and the
Tzanck smear test showed a negative morphological pattern for
herpes virus. Results of skin biopsy showed a detached and totally
necrotic epidermis and mild perivascular mononuclear cell inﬁl-
trates in the dermis (Figure 2).Figure 2 (A) Histopathological analysis showed a detached and necrotic epidermis [hem
lymphocytes in the dermis (H&E; 200).The pathological ﬁndings were compatible with SJS. Blood
culture was negative for microbial growth. A diagnosis of SJS with
a SCORTEN score of 1 was thus established. Results of lymphocyte
transformation test were positive for amoxicillin and negative for
mefenamic acid (Table 1). The patch test was also positive for
amoxicillin and negative for mefenamic acid. Therefore, the prob-
able causative agent was amoxicillin.
The patient received one dose of intravenous methylpredniso-
lone (20 mg) on the 2nd day of hospitalization (Figure 3). The
absolute CD4þ T-cell count at that time was 66 cells/mL (normal
range, >200 cells/mL). To avoid a potential HIV outbreak, we dis-
continued the use of systemic steroid. The epidermal detachment
progressed to 40% TBSA on the 3rd day of hospitalization. The
patient’s diagnosis was changed to TEN. The fever, general malaise
and appearance of new atypical target lesions continued to prog-
ress. Injections of 50 and 25mg of etanercept were administered on
the 3rd and 5th day of hospitalization, respectively. The anti-
retroviral agents nevirapine and abacavir/lamivudine were
prescribed for HIV control on the 4th day of hospitalization. The
tumor necrosis factor-a (TNF-a) level was 26.6 pg/mL (normal
range,<8.1 pg/mL) on the same day. The absolute CD4þ T-cell count
was 85 cells/mL on the 6th day of hospitalization. No fever and no
new cutaneous lesions were observed after the 6th day of hospi-
talization. Re-epithelialization of the erosions occurred on the 8th
day of hospitalization (Figure 4). Total resolution of the mucocu-
taneous lesions was noted 14 days after treating the patient with
etanercept. Furthermore, the patient’s absolute CD4þ T-cell count
had increased to 202 cells/mL by the 14th day of hospitalization. He
was discharged in a stable condition.Discussion
SJS and TEN constitute life-threatening, severe cutaneous adverse
drug reactions and reﬂect a spectrum of the same condition. By
deﬁnition, SJS causes epidermal detachment in <10% of the TBSA,
whereas TEN involves >30% of the TBSA; overlapping SJS/TEN
affects 10%e30% of the TBSA cases.4 Clinically, SJS and TEN are
characterized by the sudden onset of fever, followed by the
development of generalized erythematous to violaceous mac-
ulopapules with blister formation. In addition, conjunctivitis and
oral or genital ulcers may also develop.
HIV-seropositive patients are more susceptible to cutaneous
adverse drug reactions than the general population are.3,5
Furthermore, HIV-positive individuals have been shown to have
a poorer prognosis5 and longer hospitalization period than those
who are HIV negative.6,7 The exact mechanisms underlying this
augmented reaction in HIV-positive patients are still unclear, butatoxylineeosin (H&E) staining; 20]. (B) There was a mild perivascular inﬁltrate of
Table 1 Increases in the stimulation index determined by lymphocyte trans-
formation tests.
Agent Cytokine GNLYa MIP-1aa
Control 1 1
Amoxicillin 1.45 1.64
Mefenamic acid 0.81 0.93
GNLY ¼ granulysin; MIP-1a ¼ macrophage inﬂammatory protein-1a.
a Data are reported as “fold” increases in the stimulation index determined by
lymphocyte transformation tests.
Figure 4 Good progress in re-epithelialization was observed on the trunk. This
photograph was taken on the 10th day of hospitalization.
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bances may be contributing factors.5 CD4þ T-cell counts may be
altered by SJS/TEN. Roujeau et al8 showed that CD4þ T-cell counts
decreased in patients with TEN. Azukizawa demonstrated that
in vivo deletion of CD4þ T cells induced TEN in transgenic mice.9
However, Nishio et al10 showed no statistically signiﬁcant
changes in CD4þ T-cell numbers in patients with SJS. Jao et al11
reported decreased CD4þ cell counts during the onset of SJS in an
HIV-infected patient and elevation of CD4þ cell counts after full
recovery from SJS.
The treatment strategy for SJS/TEN involves eliminating the
causative agents and decreasing the inﬂammatory damage to the
epidermis. Systemic steroid administration is frequently used for
SJS/TEN. However, use of systemic steroid in HIV-positive individ-
uals is still controversial.12e14 Even a transient increase in HIV RNA
levels was found after the administration of a systemic steroid.14
Moreover, it has been reported that continued systemic steroid
administration is not associated with improvements in mortality
rates or wound healing in patients with SJS/TEN.1,7
Inﬁltrates of cytotoxic T lymphocytes and increased amounts of
TNF-a were observed in the epidermis of TEN lesions.15 Paul et al15
elucidated that TNF-a released by cytotoxic T lymphocytes could
induce epidermal apoptosis by binding to TNF-a receptors on the
cell surface of keratinocytes in TEN lesions. Then, extensive
epidermal destruction began. Thus, TNF-a inhibitor may be an
effective agent to decrease epidermal apoptosis among patients
with TEN. Furthermore, higher serum levels of TNF-a are associatedFigure 3 Chronology of the vital signs and treatment course in our patient.
D ¼ discharged; E ¼ etanercept; M ¼methylprednisolone; T ¼ body temperature (C);
TBSA ¼ total body surface area; P ¼ pulse rate (beats per minute); R ¼ respiratory rate
(breaths per minute). The ordinal numbers represent time points during
hospitalization.with HIV progression, including reduced immunocompetency and
debilitating symptoms such as fever and cachexia.16 Etanercept is
a recombinant fusion protein that acts as a TNF-a inhibitor. The
structure of etanercept includes a soluble TNF-a receptor linked to
the Fc subunit of human immunoglobulin G1.17 Etanercept has been
used for the treatment of TEN.18,19 Infection andmalignancy are the
main concerns over the use of etanercept. However, Ting et al20
reviewed studies before 2005 and reported that administration of
TNF-a antagonists to HIV-positive patients did not result in
increases in morbidity and mortality rates, even when accompa-
nied by a decrease in CD4þ cell counts or increased HIV RNA levels.
Cepeda et al21 also reported stable CD4þ T cell counts and HIV viral
load level without any other signiﬁcant adverse effects in eight
HIV-positive patients with rheumatic disease who underwent anti-
TNF therapy and were monitored for 28.1 months. Out of these
eight patients, only four received etanercept, whereas the other
four received etanercept and other TNF-a inhibitors.21 Results of
many other studies neither showed increased HIV viral load nor
other detectable side effects in HIV-positive patients with concur-
rent rheumatoid arthritis, psoriasis, or hepatitis C infection under
the treatment of etanercept.16,22,23Wallis et al24 even showed a 25%
increase in CD4þ T-cell count and stable HIV viral load in 16 HIV-
infected patients undergoing etanercept treatment. TNF-a could
be a target for the treatment of patients with concurrent HIV and
SJS/TEN. Our patient did not undergo an HIV follow-up for 6
months before presenting to our emergency department. Thus, we
were unable to identify whether the etanercept injections
impacted CD4þ cell counts or HIV RNA levels. However, the
patient’s CD4þ T-cell counts increased, and complete healing of the
mucocutaneous lesions occurred within 2 weeks of etanercept
treatment.
Y.-Y. Lee et al. / Dermatologica Sinica 31 (2013) 78e81 81To the best of our knowledge, no previous reports describe the
use of etanercept to treat STS/TEN in patients with HIV/AIDS. We
show here that short-term etanercept treatment for SJS/TEN in
patients with HIV/AIDS can be highly successful. Large randomized
controlled studies should be performed to conﬁrm the safety and
efﬁcacy of etanercept to treat SJS/TEN in patients with HIV/AIDS.
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